P3 Health Partners (PIII) Expected to Release Quarterly Earnings on Monday

Posted by George Bondi on Nov 2nd, 2026

P3 Health Partners (NASDAQ:PIII – Get Free Report) is projected to post its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect P3 Health Partners to announce earnings of ($3.9650) per share and revenue of $384.95 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.

P3 Health Partners (NASDAQ:PIII – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($1.89) by $1.26. The firm had revenue of $386.38 million for the quarter, compared to analyst estimates of $377.80 million.

P3 Health Partners Trading Up 4.2%

Shares of NASDAQ:PIII traded up $0.17 during midday trading on Monday, hitting $4.20. The stock had a trading volume of 213 shares, compared to its average volume of 418,325. The stock has a 50 day moving average price of $6.74 and a two-hundred day moving average price of $6.55. The company has a market capitalization of $30.49 million, a PE ratio of -0.13 and a beta of 1.81. P3 Health Partners has a 1 year low of $1.52 and a 1 year high of $16.89.

Analysts Set New Price Targets

Several analysts have commented on PIII shares. Lake Street Capital reaffirmed a “buy” rating and issued a $23.00 target price on shares of P3 Health Partners in a research note on Tuesday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of P3 Health Partners in a report on Tuesday, August 25th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $17.00.

Check Out Our Latest Analysis on P3 Health Partners

Insiders Place Their Bets

In other news, major shareholder Hudson Vegas Investment Spv, L sold 50,000 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $16.48, for a total value of $824,000.00. Following the completion of the sale, the insider owned 48,959 shares in the company, valued at $806,844.32. This represents a 50.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 10.86% of the stock is currently owned by corporate insiders.

About P3 Health Partners

(Get Free Report)

P3 Health Partners Inc is a physician-led healthcare company focused on value-based care for Medicare Advantage beneficiaries. The company works with primary care physicians, specialists, health plans and community organizations to coordinate care and improve health outcomes while addressing patients’ medical and social needs.

Its services include primary care support, care coordination, chronic-condition management, preventive care, medication management and patient navigation. P3’s model uses an integrated care team and data-driven clinical programs to help physicians manage the health of senior populations across the care continuum.

Founded in 2017, P3 Health Partners became a publicly traded company in 2021 through a business combination with Foresight Acquisition Corp.